Bipolar depression: Trial-based insights to guide patient care

Dialogues in Clinical Neuroscience

Volumn 10, Issue 2, 2008, Pages 181-192

  Kemp, David E ^a,d   Muzina, David J ^b   McIntyre, Roger S ^c,e   Calabrese, Joseph R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d NONE   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Anticonvulsant; Atypical antipsychotic; Bipolar depression; Bipolar disorder; Maintenance trial; Number needed to treat; Unimodal antidepressant

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ARMODAFINIL; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; CARBAMAZEPINE; DRUG METABOLITE; FLUOXETINE; IMIPRAMINE; INOSITOL; LAMOTRIGINE; LITHIUM; MODAFINIL; MOOD STABILIZER; NORQUETIAPINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; URIDINE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADD ON THERAPY; AKATHISIA; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; HYPERGLYCEMIA; MAINTENANCE THERAPY; MEDLINE; MONOTHERAPY; NAUSEA; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RASH; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 47749134532     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Calabrese JR, Hirschfeld RM, Frye MA, Reed ML. Impact of depressive Symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry. 2004;65:1499-1504.
2. Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: A prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62:1322-1330.
3. Tondo L, Icacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs. 2003;17:491-511.
4. Tse SS, Walsh AE. How does work work for people with bipolar affective disorder? Occup Ther Int. 2001;8:210-225.
5. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293:2528-2530.
6. Kleinman NL, Brook RA, Rajagopalan K, Gardner HH, Brizee TJ, Smeeding JE. Lost time, absence costs, and reduced productivity output for employees with bipolar disorder. J Occup Environ Med. 2005;47:1117-1124.
7. Vojta C, Kinosian B, Glick H, Altshuler L, Bauer MS. Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry. 2001;42:190-195.
8. Altshuler LL, Post RM, Black DO, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: Results of a large, multisite study. J Clin Psychiatry. 2006;67:1551-1560.
9. Judd LL, Akiskal AH, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530-537.
10. Judd LL, Akiskal AH, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261-269.
11. Suppes T, Kelly DI, Perla JM. Challenges in the management of bipolar depression. J Clin Psychiatry. 2005;66(S5):11-16.
12. Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9:531-535.
13. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163:217-224.
14. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-1547.
15. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711-1122.
16. Zornberg GL and Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol. 1993;13:397-408.
17. Cavanagh J, Smyth R, Goodwin GM. Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand. 2004;109:91-95.
18. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906-912.
19. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006;8:625-639.
20. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290:1467-1473.
21. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79-88.
22. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five, double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008;10:323-333.
23. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry. 2000;61:841-850.
24. van der Loos MLM, Zwolle IK, Vieta E, et al. Lamotrigine as add-on to lithium in bipolar depression. Poster presented at: Seventh International Conference on Bipolar Disorder, Pittsburgh, Pennsylvania; June 7-9, 2007.
25. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry. 1980;137:782-790.
26. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry. 1986;143:29-34.
27. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord. 2001;67:207-212.
28. Sachs GS, Altshuler LL, Ketter T, et al. Divalproex versus placebo for the treatment of bipolar depression. Poster presented at: American College of Neuropsychopharmacology 40th Meeting, Waikoloa, Hawaii; December 9-13, 2001.
29. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005;85:259-266.
30. Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a randomized, placebo-controlled pilot study. J Clin Psychiatry. 2007;68:1840-1844.
31. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079-1088.
32. American Diabetes Association, Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004;27:596-601.
33. Calabrese JR, Keck PE Jr., Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-1360.
34. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600-609.
35. Goldstein JM, Christoph G, Grimm S, Liu JW, Widzowski D, Brecher M. Unique mechanism of action for the antidepressant properties of the atypical antipyshcotic quetiapine. Poster presented at: 160th Annual Meeting of the American Psychiatric Association, San Diego, California; May 19-24, 2007.
36. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2004;16:189-194.
37. Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry. 2006;18:169-172.
38. Kemp DE, Dago PL, Straus J, Fleck J, Karaffa M, Gilmer WS. Aripiprazole augmentation for treatment-resistant bipolar depression: sustained remission after 36 months. J Clin Psychopharmacol. 2007;27:304-305.
39. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in non-psychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008:28;13-20.
40. Thase ME. Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep. 2006;8:478-488.
41. Cookson J, Keck PE, Ketter TA, Macfadden W. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol. 2007;22:93-100.
42. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163:210-216.
43. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003;5:421-433.
44. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013-1024.
45. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392-400.
46. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163:247-256.
47. Keck PE Jr., Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67:626-637.
48. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57:481-489.
49. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology. 2003;28:1374-1382.
50. Calabrese JR, Vieta E, El-Mallakh R, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry. 2004;56:957-963.
51. Brecher M, Liu S, Paulsson B. Quetiapine in the maintenance treatment of bipolar I disorder: combined data from two long-term, phase III studies. Poster presented at: 16th European Congress of Psychiatry, Nice, France; April 5-9, 2008.
52. Corya SA, Perlis RH, Keck PE Jr., et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 2006;67:798-806.
53. Hirschfeld RMA, Panagides J, Alphs L, Cohen M, Lancaster S, Macek T. Asenapine in acute mania: A randomized, double-blind, placebo- and olanzapine-controlled trial (ARES 7501005). Poster presented at: 160th Annual Meeting of the American Psychiatric Association, San Diego, CA; May 19-24, 2007.
54. Rapaport M, Barbato LM, Heisterberg J, Yeung PP, Shapira NA. Efficacy and safety of bifeprunox versus placebo in the treatment of patients with acute exacerbations of schizophrenia. Neuropsychopharmacology. 2006;31:S184.
55. Shapira NA, Newcomer JW, Heisterberg J, Yeung PP, Barbato LM. The metabolic profile of bifeprunox in the treatment of patients with schizophrenia. Neuropsychopharmacology. 2007;31:S175-S176.
56. Frye M, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;16:1242-1249.
57. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61:300-308.
58. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003;64:680-690.
59. Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric Services. 2007;58:85-91.
60. Altshuler LL, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry. 2003;160:1252-1262.
61. Miklowitz DJ, Ottow MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry. 2007;64:419-426.